Peptide guide

AOD-9604

A modified fragment of human growth hormone (residues 176–191) studied as a fat-loss drug — and the rare peptide where the human trials actually ran, then came up short.

AOD-9604 is a lab-made fragment of human growth hormone, the tail end of the molecule (residues 176–191), built to keep growth hormone's fat-burning behavior without its growth and blood-sugar effects. It's unusual among peptides for having real human data: six placebo-controlled trials in roughly 900 people. That data is also why it isn't a weight-loss drug today — the larger, longer obesity trial failed to beat placebo, and development was shelved in 2007. It later picked up GRAS status as a food ingredient, but it has never been FDA-approved as a medicine. People still run it subcutaneously for fat loss, so the useful questions are what the evidence actually says, how to handle it, and how not to get scammed buying it.

By the Zapify Research team

Reviewed against 6 clinical & research sources · Updated June 2026 · Educational use only

Type: 16-aa peptidehGH 176–191 fragment
Route: Subcutaneousinjection is off-trial
Typical dose: ~300 mcg/dayreported range
Cycle: Weeks, dailyno fixed standard
Storage: Mixed: 2–4 wksSealed: months
Status: Not FDA-approved

What is AOD-9604?

A 16-amino-acid synthetic fragment of growth hormone's tail (residues 176–191) built for fat burning; it doesn't raise IGF-1 and isn't FDA-approved.

AOD-9604 is a synthetic peptide, a short chain of amino acids, copied from a specific stretch of human growth hormone. Growth hormone is a 191-amino-acid protein, and the piece this peptide is built from is its tail end, residues 176 through 191. A tyrosine is added at the front to make the fragment more stable. That's the whole molecule, sixteen amino acids, and there's nothing exotic behind the name.

The design goal was specific. Full growth hormone burns fat, but it also raises IGF-1, can push blood sugar the wrong way, and drives general growth. Researchers wanted the fat-metabolism part on its own. AOD-9604 came out of that effort, and the human studies bore the separation out: it doesn't bind the growth hormone receptor and doesn't raise IGF-1, which is the main thing that sets it apart from injecting growth hormone itself.

What makes it unusual in this category is that it was taken seriously as a drug. An Australian company, Metabolic Pharmaceuticals, ran it through real clinical trials for obesity. Most peptides sold online never got that far, so AOD-9604 comes with something rare here: actual human data, including the part that didn't go the way the marketing suggests.

AOD-9604 isn't FDA-approved as a drug for weight loss or anything else. Its development for obesity was discontinued in 2007 after the larger, longer trial failed to beat placebo. It did later receive GRAS status ("generally recognized as safe") as a food ingredient, but that's a safety designation for an additive, not approval that it works or that it's a medicine. Treat it as an experimental compound, not a proven treatment.

What is it studied for?

Rare among peptides, it has real human data — six placebo-controlled trials in ~900 people — and that data is clear it fell short on fat loss.

Unlike most compounds in this space, AOD-9604 was studied in people, and at scale. A 2013 safety review pulled together six randomized, double-blind, placebo-controlled trials covering roughly 900 participants. So the evidence base isn't a pile of rat studies. It's human, and that cuts both ways: the safety read is unusually solid, and the efficacy read is unusually clear about falling short.

Evidence base, by subject

≈900Human trial participants

0Trials that hit the weight-loss endpoint

Three things the research actually established:

Fat metabolismThe original premise. In lab and animal work it pushed fat breakdown and dampened fat storage, which is what drew the anti-obesity program.

Safety & tolerabilityThe strongest human finding. Across six trials it looked indistinguishable from placebo: no IGF-1 rise, no glucose impairment, no anti-drug antibodies.

Weight loss in humansThe disappointment. An early 12-week study showed a modest edge (about 2.6 kg vs 0.8 kg for placebo), but the larger 24-week trial that followed missed its endpoint.

The mechanism is better understood here than with most peptides, at least in cells and animals: AOD-9604 appears to stimulate lipolysis (the breakdown of stored fat) and inhibit lipogenesis (the laying-down of new fat), mimicking growth hormone's effect on fat tissue without touching its receptor. What's never been settled is whether that translates into meaningful fat loss in a living human at the doses people use. The trials that tested it directly are the reason there's any doubt — the bigger, longer one leaned the wrong way.

Why people use it

People use it to chase growth hormone's fat-loss reputation without the IGF-1 spike, but the larger, longer trial didn't beat placebo.

People reach for AOD-9604 for a handful of reasons. These are why they try it, not evidence that it delivers:

Targeting stubborn fat without the appetite suppression and gut side effects of a GLP-1 drug like semaglutide.
Wanting growth hormone's fat-loss reputation without the IGF-1 spike, water retention, and blood-sugar concerns of running GH itself.
A clean safety record on paper, which makes it feel lower-risk than most research peptides to experiment with.
Stacking it alongside diet, training, or other compounds and treating it as a metabolic nudge rather than the main lever.

The human trials are the inconvenient part: in the larger, longer study, AOD-9604 didn't produce weight loss that beat placebo, which is why it never became a drug. The steelman is that those trials weren’t testing the injected route people use now, were powered for obesity as a whole-body outcome, and still came back with a safety profile clean enough to earn a food-ingredient designation. Someone injecting it subcutaneously for body composition is running a different protocol than the one that failed. That's a reason to be curious, not a reason to expect results the evidence never showed. It won't replace the things that reliably move fat: a calorie deficit, training, sleep, and protein.

How to reconstitute AOD-9604

Mix a 5 mg vial with 2 mL bacteriostatic water for 2.5 mg/mL, so 12 units draws 300 mcg; add water down the wall and swirl, don't shake.

AOD-9604 ships as a small puck of dry powder. People run it as a subcutaneous injection, so first you mix the powder into a liquid. That step is called reconstitution, and it's the same process used for most research peptides.

Step 1Start with powderWipe the rubber stopper with an alcohol swab.

Step 2Add bac. waterRun it slowly down the inside wall — never shake.

Step 3Draw your doseThe calculator gives the exact units to draw to.

Wipe the rubber stopper with an alcohol swab first, every time.
Use bacteriostatic water, not plain sterile water and not saline. The trace of benzyl alcohol in it holds back bacteria, which matters because you'll be drawing from the same vial for weeks.
Add the water slowly, running it down the inside glass wall. Don't blast it straight onto the powder.
Don't shake it. Swirl gently and let it dissolve on its own. Shaking foams the solution and can damage the peptide.

A common setup is a 5 mg vial mixed with 2 mL of bacteriostatic water, which gives 2.5 mg/mL. On a U-100 insulin syringe, 12 units is then 300 mcg, a typical reported daily dose. The water doesn't change how much peptide is in the vial; it only sets the concentration, which decides how many units you draw. More water means a more dilute mix and a bigger draw for the same dose. You can't ruin it with too much or too little, you only change the draw math, and that's exactly what the calculator handles.

Calculate your exact AOD-9604 reconstitution →

Dose & units

No FDA dose; reports cite about 300 mcg subcutaneously once daily (range ~200–500 mcg), often morning on an empty stomach, run for roughly 12 weeks.

There is no FDA-approved dose for AOD-9604. The numbers below are what clinics and write-ups report, not a medical standard, and they describe subcutaneous use that the trials never tested. The clinical program dosed it orally and still didn't clear the bar for approval. Decide what goes into your body with a licensed provider, not with this page.

Typical range

The most commonly reported subcutaneous dose is around 300 mcg once a day, with the broader reported range running roughly 200–500 mcg daily. (A microgram, or mcg, is a thousandth of a milligram.) Many protocols suggest dosing in the morning on an empty stomach, on the theory that food and circulating insulin blunt fat breakdown, though that timing is convention rather than something the trials pinned down.

Titration

Most write-ups start near the low end, around 200–300 mcg a day, and hold there. Because the reported side-effect profile is mild, titration here is less about managing reactions and more about not overspending on a compound whose human efficacy is unproven. There's no medal for starting high.

Cycling

Reported protocols usually run daily for a stretch of weeks, commonly cited as something like 12 weeks, then a break, but there's no established cycle the way there is for some peptides. The clinical trials dosed continuously for 12 to 24 weeks, so the open-ended "run it daily for a few months" pattern people use loosely mirrors the trial duration rather than any tested on/off schedule.

On~12 weeks daily

Offbreak, then reassess

For the exact mark to draw to on your insulin syringe, don't eyeball it. The calculator turns your vial size, water, and dose into the precise number of units.

Get your exact units →

Storage

Sealed powder is stable for months at room temperature; once mixed, refrigerate and use within about 2–4 weeks.

Sealed & drySealed dry powder stays stable for months at room temperature and shrugs off shipping heat.

ReconstitutedRefrigerate at 2–8 °C and use within about 2–4 weeks; don't freeze, keep out of light, discard if cloudy or discolored.

You'll see longer windows quoted for peptide vials. Those figures are beyond-use dates for a sealed, unmixed vial that a compounding pharmacy has stability-tested, and they stop applying the moment you add water. A mixed vial runs on the shorter clock instead, because that's how long the preservative in bacteriostatic water reliably keeps the solution clean once you're drawing from it.

That limit is about contamination, not potency — the peptide itself often stays good well beyond it. Reconstitute with plain sterile water instead of bacteriostatic and you drop to a day or two, since there's no preservative holding bacteria back.

Don't freeze a reconstituted vial, keep it out of direct light, write the mix date on the label, and throw it out if the solution ever turns cloudy or discolored, whatever the date says.

Side effects & safety

Across six trials its profile matched placebo with no IGF-1 rise or glucose problems, but those trials didn't test the subcutaneous route people use; WADA-prohibited.

On safety, AOD-9604 has the best human paper trail of almost any peptide sold this way. Across six controlled trials its profile was indistinguishable from placebo: no rise in IGF-1, no impairment of glucose tolerance, no anti-drug antibodies, and no treatment-related serious adverse events. That's a genuinely reassuring record, with the caveat that those trials didn’t test the subcutaneous injection people use now, which sits slightly outside what was formally studied.

Most common: mild, short-lived redness or irritation at the injection site.
Less often: mild headache, some nausea, or temporary dizziness, generally reported as minor.
Not seen in the trials, despite the growth-hormone origin: IGF-1 elevation, insulin resistance, or glucose problems.

A clean trial record isn't a personal guarantee. The trials studied screened participants over short courses, not long-term self-injection, and they tell you nothing about how a given vial off the gray market behaves. Talk to a doctor before starting if you're pregnant, breastfeeding, managing diabetes or a blood-sugar condition, or have a history of cancer. The fat-metabolism mechanism isn't a known cancer risk, but anything derived from growth hormone deserves a real conversation, not a shrug.

If you compete, AOD-9604 is prohibited by WADA as a growth factor (it falls under the S2 peptide-hormone and growth-factor category, named as a growth hormone fragment), banned in and out of competition. Using it is a doping violation.

And the biggest risk here isn't really the molecule, which has a cleaner safety record than most. It's whether what's in the vial is actually AOD-9604, at the strength on the label. That comes down to where you buy it.

How to vet a source

The clinical data describes pharmaceutical material, not your vial — get a batch-specific COA and match the lot number before you buy.

AOD-9604's reputation rests on its clinical-grade safety data, and that reputation does you no good if the vial in your hand is underdosed, impure, or a different compound entirely. This is an unregulated market, and a real share of independently tested vials come back as none of what the label claims. The trial data describes pharmaceutical material; it says nothing about a random gray-market batch. Where you buy matters more than almost anything else here. The one document that separates a real seller from a gamble is a certificate of analysis: a third-party lab's report on what's actually in the vial.

A real COA shows

An identity test (usually mass spectrometry) confirming the peptide is what the label says.
A purity figure from HPLC, typically 98% or higher.
A lot or batch number that matches the number printed on your vial.
A named, independent accredited lab and a recent test date.

Walk away if

There’s no COA, or it’s a generic image with no lot number.
The “certificate” comes from the seller instead of a third-party lab.
The lot number doesn’t match your vial, or there isn’t one at all.
It’s a flat image you can’t trace back to the lab that issued it.

That's the standard worth holding any seller to, ours included. Ask for the batch-specific COA before you buy, match the lot number to your vial, and don't accept a screenshot in place of a traceable report.

See the Zapify compound catalog →

Common questions about AOD-9604

Does AOD-9604 actually work for weight loss?

The human trials lean no, at least not at a level that held up. Six controlled trials in about 900 people were run. An early 12-week dose-ranging study (about 300 obese adults) showed a modest edge — roughly 2.6 kg versus 0.8 kg for placebo at the best dose — but the larger 24-week trial that followed (536 adults) failed to produce weight loss strong enough to support a drug, and development was discontinued in 2007. People still use it subcutaneously for body composition, but they're going beyond what the evidence supports.

Is AOD-9604 FDA-approved?

Not as a drug. It was never approved for weight loss or any other medical use, and its obesity development was shelved after the trials. It did receive GRAS status ("generally recognized as safe") as a food ingredient in some contexts, which is a safety designation for an additive, not approval that it treats anything or that it works.

How is AOD-9604 different from growth hormone or HGH fragment 176-191?

AOD-9604 is the 176–191 tail of growth hormone with a stabilizing tyrosine added at the front (because of that added residue, the literature also numbers it 177–191; it's the same compound). Compared with full growth hormone, it doesn't bind the GH receptor and doesn't raise IGF-1, so it skips the growth, water-retention, and blood-sugar effects while keeping the fat-metabolism behavior, at least in the lab. "HGH fragment 176-191" usually refers to the same underlying sequence; AOD-9604 is the modified, stabilized version that actually went through clinical trials.

Is AOD-9604 banned in sport?

Yes. WADA prohibits it as a growth factor under the S2 peptide-hormone and growth-factor category, where it's specifically named as a growth hormone fragment, banned both in and out of competition. For a tested athlete, using it is a doping violation regardless of the dose.

Why is the safety data good but the efficacy bad?

Those are two separate questions, and AOD-9604 happens to split them cleanly. The trials were designed in part to confirm it didn't carry growth hormone's downsides, and on that front it passed: no IGF-1 rise, no glucose impairment, no antibodies. But safe and effective aren't the same thing. In the larger, longer trial, it didn't produce meaningful weight loss over placebo, which is why a compound with a clean safety sheet still isn't a drug.

References

This page is for research and educational purposes only. It is not medical advice or a recommendation to use any compound. The dose ranges shown are reported by clinics and research literature, not validated medical standards, and AOD-9604 is not FDA-approved. Talk to a licensed medical provider about anything you put in your body.